Paragon Private Wealth Management’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Paragon Private Wealth Management’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-26,185	Closed	-$686K	–	130
2023 Q2	$686K	Buy	26,185 +4,518	+21%	+$119K	0.55%	65
2023 Q1	$565K	Buy	21,667 +8,377	+63%	+$225K	0.48%	67
2022 Q4	$365K	Buy	+13,290	New	+$354K	0.33%	84

Other funds holding FTXH

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

KNW

Kesler Norman & Wride Ogden, Utah $631M AUM 27.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

WFA

WMG Financial Advisors Knoxville, Tennessee $265M AUM 26.03% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return

OWA

Outlook Wealth Advisors Shenandoah, Texas $413M AUM 19.55% 1-Year Est. Return

Paragon Private Wealth Management's FTXH Position: Q3 2023 in Review

Paragon Private Wealth Management sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q3 2023, closing a stake of 26,185 shares — an estimated $686K sold.

Paragon Private Wealth Management first reported a position in FTXH in Q4 2022 and held it in 3 quarters. The position peaked at $686K in Q2 2023. 19 funds tracked by Wall St. Rank hold FTXH as of Q3 2023.

Paragon Private Wealth Management reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q3 2023 after selling out during the quarter.
Paragon Private Wealth Management sold 26,185 First Trust Nasdaq Pharmaceuticals ETF shares in Q3 2023, an estimated $686K.
Paragon Private Wealth Management first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q4 2022 and held it in 3 quarters.
Paragon Private Wealth Management's First Trust Nasdaq Pharmaceuticals ETF position peaked at $686K in Q2 2023.
19 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q3 2023.

Based on Paragon Private Wealth Management's 13F filing for Q3 2023, filed 13 Nov 2023.